Cost per responder analysis of guselkumab versus targeted therapies in the treatment of moderate to severe plaque psoriasis in Germany
Background The fully human monoclonal antibody guselkumab is an effective treatment option for patients with moderate to severe psoriasis. Objective The objective of this study was to examine the cost per responder of guselkumab compared with other targeted therapies for the treatment of moderate to...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-02-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/09546634.2020.1793891 |